Fig. 5
From: Treating sex and gender differences as a continuous variable can improve precision cancer treatments
Example application of TI in patient treatment stratification. Pictured are the TI distributions for female (top panel) and male (bottom panel) lung adenocarcinoma (LUAD) patients. Females exhibited a strong immunity/inflammation signature and in clinical trials, are resistant to immune checkpoint inhibition (ICI). In contrast, male LUAD patients do not exhibit an inflammation/immunity signature and are responsive to ICI. If male and female patients were stratified for immune checkpoint inhibition treatment, the most likely males to respond to treatment would be those with the highest TI, those nearest the male pole. Female patients most likely to respond to treatment would also be those with the highest TI values, those furthest from the female pole